EA201692031A1 - Фармацевтическая композиция с активным действием в отношении хронических бактериальных инфекций - Google Patents

Фармацевтическая композиция с активным действием в отношении хронических бактериальных инфекций

Info

Publication number
EA201692031A1
EA201692031A1 EA201692031A EA201692031A EA201692031A1 EA 201692031 A1 EA201692031 A1 EA 201692031A1 EA 201692031 A EA201692031 A EA 201692031A EA 201692031 A EA201692031 A EA 201692031A EA 201692031 A1 EA201692031 A1 EA 201692031A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bacterial infections
respect
pharmaceutical composition
chronic bacterial
active action
Prior art date
Application number
EA201692031A
Other languages
English (en)
Inventor
Стефан Миллер
Ивз Бриерс
Роб Лавигне
Original Assignee
Лисандо Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50439296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201692031(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Лисандо Аг filed Critical Лисандо Аг
Publication of EA201692031A1 publication Critical patent/EA201692031A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01028—N-Acetylmuramoyl-L-alanine amidase (3.5.1.28)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Insects & Arthropods (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Abstract

Заявленное изобретение относится к полипептиду, содержащему гидролазу пептидогликана, для применения в качестве лекарственного препарата в лечении хронических бактериальных инфекций. Заявленное изобретение также относится к полипептиду, содержащему гидролазу пептидогликана, включающую эндопептидазу, N-ацетил-мурамоил-L-аланин-амидазу, N-ацетил-мурамидазу, N-ацетил-глюкозаминидазу и/или литическую трансгликозилазу.
EA201692031A 2014-04-08 2015-04-08 Фармацевтическая композиция с активным действием в отношении хронических бактериальных инфекций EA201692031A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14163927 2014-04-08
PCT/EP2015/057625 WO2015155244A1 (en) 2014-04-08 2015-04-08 Pharmaceutical composition against chronic bacterial infections

Publications (1)

Publication Number Publication Date
EA201692031A1 true EA201692031A1 (ru) 2017-07-31

Family

ID=50439296

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692031A EA201692031A1 (ru) 2014-04-08 2015-04-08 Фармацевтическая композиция с активным действием в отношении хронических бактериальных инфекций

Country Status (6)

Country Link
US (1) US20170106058A1 (ru)
EP (1) EP3129044B1 (ru)
AU (1) AU2015243359B2 (ru)
CA (1) CA2941426C (ru)
EA (1) EA201692031A1 (ru)
WO (1) WO2015155244A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015155244A1 (en) 2014-04-08 2015-10-15 Lysando Ag Pharmaceutical composition against chronic bacterial infections
WO2017186942A1 (en) * 2016-04-28 2017-11-02 Lysando Ag Antimicrobial agents against salmonella bacteria
EP3464583A1 (en) 2016-05-27 2019-04-10 Sasinapas Co., Ltd. Endolysin variant
CN106701690A (zh) * 2016-12-13 2017-05-24 上海交通大学医学院 鲍曼不动杆菌噬菌体SH‑Ab15519及其应用
CN107298707B (zh) * 2017-07-31 2020-05-08 河南科技学院 一种类Bac5抗菌肽及其应用
EP4295902A3 (en) * 2018-05-03 2024-06-19 Crigasseni AG Probiotic bacterial strains producing antimicrobial proteins and compositions comprising these for use in the treatment of clostridium difficile infection
US20210169985A1 (en) * 2018-05-04 2021-06-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating gram positive bacterial infection
AU2019276252A1 (en) * 2018-05-30 2020-11-26 Lysando Ag Novel antimicrobial fusion proteins
CN112166190A (zh) 2018-05-30 2021-01-01 莱桑多公司 新抗微生物蛋白
US11959111B2 (en) 2018-12-21 2024-04-16 Novozymes A/S Polypeptides having peptidoglycan degrading activity and polynucleotides encoding same
GB201906653D0 (en) * 2019-05-10 2019-06-26 Cc Biotech Ltd Polypeptides for treatment of bacterial infections
CN110903404A (zh) * 2019-12-30 2020-03-24 佛山科学技术学院 一种蜂毒素-死亡素重组多肽及其应用
CN111349177B (zh) * 2020-03-13 2022-04-22 西北农林科技大学 一种融合抗菌肽cat的制备方法和应用
CN116121110A (zh) * 2022-10-28 2023-05-16 益加生物科技成都有限公司 一种抑菌和抗炎作用较强的乳酸乳球菌yj0801及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0815484D0 (en) * 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
WO2010141135A2 (en) * 2009-03-05 2010-12-09 Trustees Of Boston University Bacteriophages expressing antimicrobial peptides and uses thereof
ES2579806T3 (es) * 2009-06-26 2016-08-16 Katholieke Universiteit Leuven, K.U. Leuven R&D Agentes antimicrobianos
CA2772001A1 (en) * 2009-08-24 2011-03-03 Katholieke Universiteit Leuven, K.U. Leuven R&D New endolysin obpgplys
CA2794603C (en) * 2010-04-27 2019-05-21 Lysando Ag Method of reducing biofilms
EP2468856A1 (en) * 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
SG11201600180WA (en) 2013-07-11 2016-02-26 Micreos Human Health Bv Combination treatment for atopic dermatitis
WO2015155244A1 (en) 2014-04-08 2015-10-15 Lysando Ag Pharmaceutical composition against chronic bacterial infections

Also Published As

Publication number Publication date
WO2015155244A1 (en) 2015-10-15
EP3129044B1 (en) 2022-09-07
EP3129044A1 (en) 2017-02-15
CA2941426C (en) 2022-09-27
CA2941426A1 (en) 2015-10-15
US20170106058A1 (en) 2017-04-20
AU2015243359B2 (en) 2020-03-12
AU2015243359A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
EA201692031A1 (ru) Фармацевтическая композиция с активным действием в отношении хронических бактериальных инфекций
EA201892386A1 (ru) Химерные нейротоксины
EA201890204A1 (ru) Антибактериальные соединения
EA201990043A1 (ru) Антибактериальные соединения
EA201791866A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201991157A1 (ru) Доставка белков на основе бактерий, аттенуированных по вирулентности
EA201791775A1 (ru) Цистеиновая протеаза
MX2017005575A (es) Formulacion farmaceutica de anticuerpos anti-tnf alfa.
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
MX360041B (es) Composiciones y metodos para el cuidado personal.
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201692007A1 (ru) Соединения изоиндолинона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений
EA201690159A1 (ru) Способы и композиции для лечения рака
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
EA201692025A1 (ru) Доставка белков, осуществляемая на основе бактерий
CL2015002897A1 (es) Inhibidores de bace1
EA201692552A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
CL2015002620A1 (es) Derivados piridin-4-ilo
EA201992175A1 (ru) Композиции и способы, включающие пробиотические молекулы
EA201692284A1 (ru) Ниацинамид для стимуляции продуцирования антимикробных пептидов
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
MX2017003121A (es) Formulaciones de anticuerpos.
EA201690859A1 (ru) Предотвращение инфекций, вызываемых staphylococcus aureus, гликопротеиновыми вакцинами, синтезированными в escherichia coli